Sequence-dependent toxicity profile in modified famtx (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study

Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer

“…The results of a phase III multicenter trial by the European Organization for Treatment of Cancer (EORTC) demonstrated that the FAMTX regimen yielded a superior response rate and survival with less hematologic toxicity, compared with 5-FU ϩ Adriamycin ϩ mitomyciu C (FAM) [8]. Based on these results, FAMTX appeared to have become a standard regimen for gastric cancer in the United States and Europe during the 1990s [9][10][11][12][13], and a pilot study to evaluate the therapeutic effect of FAMTX for patients with unresectable scirrhous gastric cancer was conducted at our institution. Four of 12 patients (33%) treated with FAMTX showed a partial response, which was the highest response rate shown for scirrhous gastric cancer among the many regimens attempted in our institution.…”

Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer

“…The results of a phase III multicenter trial by the European Organization for Treatment of Cancer (EORTC) demonstrated that the FAMTX regimen yielded a superior response rate and survival with less hematologic toxicity, compared with 5-FU ϩ Adriamycin ϩ mitomyciu C (FAM) [8]. Based on these results, FAMTX appeared to have become a standard regimen for gastric cancer in the United States and Europe during the 1990s [9][10][11][12][13], and a pilot study to evaluate the therapeutic effect of FAMTX for patients with unresectable scirrhous gastric cancer was conducted at our institution. Four of 12 patients (33%) treated with FAMTX showed a partial response, which was the highest response rate shown for scirrhous gastric cancer among the many regimens attempted in our institution.…”

Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer

“…The results of a phase III multicenter trial by the European Organization for Treatment of Cancer (EORTC) demonstrated that the FAMTX regimen yielded a superior response rate and survival with less hematologic toxicity, compared with 5-FU ϩ Adriamycin ϩ mitomyciu C (FAM) [8]. Based on these results, FAMTX appeared to have become a standard regimen for gastric cancer in the United States and Europe during the 1990s [9][10][11][12][13], and a pilot study to evaluate the therapeutic effect of FAMTX for patients with unresectable scirrhous gastric cancer was conducted at our institution. Four of 12 patients (33%) treated with FAMTX showed a partial response, which was the highest response rate shown for scirrhous gastric cancer among the many regimens attempted in our institution.…”

Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer

“…The results of a phase III multicenter trial by the European Organization for Treatment of Cancer (EORTC) demonstrated that the FAMTX regimen yielded a superior response rate and survival with less hematologic toxicity, compared with 5-FU ϩ Adriamycin ϩ mitomyciu C (FAM) [8]. Based on these results, FAMTX appeared to have become a standard regimen for gastric cancer in the United States and Europe during the 1990s [9][10][11][12][13], and a pilot study to evaluate the therapeutic effect of FAMTX for patients with unresectable scirrhous gastric cancer was conducted at our institution. Four of 12 patients (33%) treated with FAMTX showed a partial response, which was the highest response rate shown for scirrhous gastric cancer among the many regimens attempted in our institution.…”